5-methoxy-[1,2,4]triazin-6-ylmethylamine | 1196395-68-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-methoxy-[1,2,4]triazin-6-ylmethylamine
• 英文别名: 1-(5-methoxy-[1,2,4]triazin-6-yl)-methylamine；5-Methoxy-1,2,4-triazine-6-methanamine；(5-methoxy-1,2,4-triazin-6-yl)methanamine
• CAS: 1196395-68-2
• 化学式: C₅H₈N₄O
• mdl: MFCD19207956
• 分子量: 140.145
• InChiKey: ZARZKWCZZDQPIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-methoxy-[1,2,4]triazin-6-ylmethylamine 在 碳酸氢钠 、 三氯氧磷 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 3-(4-methoxyimidazo[5,1-f][1,2,4]triazin-7-yl)cyclobutanone
  参考文献：
  名称：

  Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR

  摘要：

  This report describes the investigation of a series of 5,7-disubstituted imidazo[5,1-f][1,2,4]triazine inhibitors of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR). Structure-activity relationship exploration and optimization leading to the identification, characterization, and pharmacological activity of compound 9b, a potent, selective, well-tolerated, and orally bioavailable dual inhibitor of IGF-1R and IR with in vivo efficacy in tumor xenograft models, is discussed.

  DOI：

  10.1021/ml100178g
• 作为产物：
  描述：

  氮气 、 6-(Azidomethyl)-5-methoxy-1,2,4-triazine 在 钯 氮气 、 氢气 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以to give 1-(5-methoxy-[1,2,4]triazin-6-yl)-methylamine which的产率得到5-methoxy-[1,2,4]triazin-6-ylmethylamine
  参考文献：
  名称：

  SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES

  摘要：

  具有公式I结构的融合吡啶基双环化合物，其药学上可接受的盐，制备、组成和用于治疗疾病。本摘要不定义或限制该发明。

  公开号：

  US20090286768A1

文献信息

• Synthetic approaches to 5,7-disubstituted imidazo[5,1-f][1,2,4]triazin-4-amines
  作者：Douglas S. Werner、Hanqing Dong、Mridula Kadalbajoo、Radoslaw S. Laufer、Paula A. Tavares-Greco、Brian R. Volk、Mark J. Mulvihill、Andrew P. Crew

  DOI：10.1016/j.tetlet.2010.05.083

  日期：2010.7

  7-disubstituted imidazo[5,1-f][1,2,4]triazin-4-amines, exemplified by 5-[3-(benzyloxy)phenyl]-7-cyclobutylimidazo[5,1-f][1,2,4]triazin-4-amine, was developed through a linear and three convergent synthetic strategies, with the latter providing the greatest flexibility for diversification at the 5-position at the last step of the synthesis.

  5,7-二取代的咪唑并[5,1- f ] [1,2,4]三嗪-4-胺的制备，以5- [3-（苄氧基）苯基] -7-环丁基咪唑并[5,1- ]为例f ] [1,2,4] triazin-4-amine是通过线性和三种收敛合成策略开发的，后者在合成的最后一步为5位多样化提供了最大的灵活性。
• SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES
  申请人：Crew Andrew P.

  公开号：US20090286768A1

  公开（公告）日：2009-11-19

  Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention.

  具有公式I结构的融合吡啶基双环化合物，其药学上可接受的盐，制备、组成和用于治疗疾病。本摘要不定义或限制该发明。
• Discovery of an Orally Efficacious Imidazo[5,1-<i>f</i>][1,2,4]triazine Dual Inhibitor of IGF-1R and IR
  作者：Meizhong Jin、Prafulla C. Gokhale、Andy Cooke、Kenneth Foreman、Elizabeth Buck、Earl W. May、Lixin Feng、Mark A. Bittner、Mridula Kadalbajoo、Darla Landfair、Kam W. Siu、Kathryn M. Stolz、Douglas S. Werner、Radoslaw S. Laufer、An-Hu Li、Hanqing Dong、Arno G. Steinig、Andrew Kleinberg、Yan Yao、Jonathan A. Pachter、Robert Wild、Mark J. Mulvihill

  DOI：10.1021/ml100178g

  日期：2010.12.9

  This report describes the investigation of a series of 5,7-disubstituted imidazo[5,1-f][1,2,4]triazine inhibitors of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR). Structure-activity relationship exploration and optimization leading to the identification, characterization, and pharmacological activity of compound 9b, a potent, selective, well-tolerated, and orally bioavailable dual inhibitor of IGF-1R and IR with in vivo efficacy in tumor xenograft models, is discussed.
• Substituted imidazopyr- and imidazotri-azines
  申请人：Crew Andrew P.

  公开号：US08481733B2

  公开（公告）日：2013-07-09

  Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention.

  具有以下公式结构的融合吡啶基双环化合物，其药学上可接受的盐，制备方法，组合物以及用于疾病治疗的方法。本摘要不定义或限制发明。